425: Medera Announces Positive Progress in Phase 1/2a Clinical Trial for Heart Failure Gene Therapy

Medera's gene therapy subsidiary, Sardocor Corp., has completed Cohort A and initiated dosing in Cohort B of its MUSIC-HFpEF Phase 1/2a clinical trial evaluating SRD-002 for Heart Failure with Preserved Ejection Fraction (HFpEF).

Summary

• Medera Inc. has announced the completion of Cohort A and the initiation of dosing in Cohort B of the MUSIC-HFpEF Phase 1/2a clinical trial.
• The trial is evaluating SRD-002, a first-in-human gene therapy for Heart Failure with Preserved Ejection Fraction (HFpEF).
• Cohort A involved a low dose of SRD-002 (3x10^13 vg per patient) and Cohort B involves a high dose (4.5x10^13 vg per patient).
• Promising efficacy results were observed in Cohort A at the six-month mark, with additional data being collected.
• Enrollment in Cohort B is expected to be completed in the first quarter of 2025, with an interim data readout anticipated in the first half of 2025.
• HFpEF affects nearly half of all heart failure cases and has limited disease-modifying therapeutics.
• Medera and Keen Vision Acquisition Corporation (KVAC) announced a definitive merger agreement on September 5, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the promising efficacy results in Cohort A and the initiation of Cohort B. However, the forward-looking statements and associated risks temper the overall sentiment.

Positives

• Promising efficacy results were observed in Cohort A at the six-month mark.
• SRD-002 has been well tolerated with no unexpected events or toxicities observed.
• The FDA granted Fast Track Designation for MUSIC-HFpEF.
• The Data Safety Monitoring Board (DSMB) recommended proceeding to Cohort B.
• Medera's mini-Heart technology, co-developed with AstraZeneca, has shown improved relaxation defects with SRD-002 delivery.

Negatives

• HFpEF has limited disease-modifying therapeutics, highlighting the critical need for new interventions.

Risks

• The forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.
• These risks include the possibility that the merger with KVAC may not be completed, the inability to maintain the listing of KVAC's or Medera's securities on Nasdaq, and the risk that Medera will need to raise additional capital to execute its business plan.
• There are also risks related to regulatory review, approval, and commercial development, as well as risks associated with intellectual property protection.

Future Outlook

Medera expects to complete enrollment in Cohort B in the first quarter of 2025, with an interim data readout anticipated in the first half of 2025. The company aims to develop SRD-002 as a potential effective treatment for HFpEF patients.

Management Comments

• Marat Fudim, MD, MHS, stated that new treatment approaches, like Medera's gene therapy product, are critical for patients and caregivers faced with this devastating disease.
• Roger Hajjar, MD, stated that the progression of MUSIC-HFpEF is a key milestone in the clinical development of SRD-002 as a potential effective treatment for HFpEF patients.

Industry Context

The announcement addresses the significant unmet need for disease-modifying therapeutics for HFpEF, a condition affecting nearly half of all heart failure cases globally. The success of Medera's gene therapy could provide a new treatment option for this prevalent condition.

Comparison to Industry Standards

• The document mentions sacubitril-valsartan (Entresto) and the sodium glucose transporter-2 (SGLT-2) inhibitor empagliflozin (Jardiance) as existing treatments for reducing cardiovascular mortality and heart failure hospitalization in HFpEF patients.
• However, it notes that these agents are not disease-modifying, highlighting the potential advantage of Medera's SRD-002 if it proves to be disease-modifying.

Stakeholder Impact

• Positive impact on HFpEF patients and caregivers due to the potential for a new treatment option.
• Potential positive impact on shareholders of Medera and KVAC if the merger is completed and SRD-002 is successful.
• Positive impact on Medera employees through the advancement of the company's clinical programs.

Next Steps

• Complete enrollment in Cohort B of the MUSIC-HFpEF trial.
• Analyze additional data from Cohort A.
• Conduct an interim data readout from Cohort B in the first half of 2025.
• Continue clinical development of SRD-002.

Key Dates